Eli Lilly Invests $3B in Wisconsin Plant to Meet Obesity Drug Demand
TL;DR Summary
Eli Lilly is investing $3 billion to expand its manufacturing plant in Pleasant Prairie, Wisconsin, to meet the growing demand for its weight-loss and diabetes drugs, including Zepbound and Mounjaro. This expansion is part of Lilly's broader $23 billion investment strategy in manufacturing since 2020. The company plans to add 750 jobs to the Wisconsin site, with construction starting next year and production expected by the end of 2025. This move comes amid competition with Novo Nordisk, which is also increasing its manufacturing capabilities for similar drugs.
- Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars CNBC
- Lilly to Boost Weight-Loss Drug Supply With $3 Billion Expansion Bloomberg
- Lilly continues to expand its empire of GLP-1 factories with new $3B buildout Endpoints News
- On an investment spree, Lilly will spend $3B to expand newly acquired injectables plant in Wisconsin FiercePharma
- Eli Lilly announce $3 billion expansion at Pleasant Prairie facility WISN Milwaukee
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
1 min
vs 2 min read
Condensed
77%
374 → 87 words
Want the full story? Read the original article
Read on CNBC